Obstructive sleep apnea/hypopnea (OSAH) has a strong heritable component, although its genetic basis remains largely unknown. One epidemiologic study found a significant association between the APOE ⑀4 allele and OSAH in middle-aged adults, a finding that was not replicated in a cohort of elderly adults. The objective of this study was to further examine the association of the APOE ⑀4 allele with OSAH in a community-dwelling cohort, exploring age dependency of the association. Methods: A genetic association study was performed, nested within a prospective cohort study of the cardiovascular consequences of OSAH. Unattended, in-home nocturnal polysomnography was used to measure apnea-hypopnea index (AHI) in 1,775 participants age 40 to 100 years. OSAH was defined as an AHI Ն 15. The relation of APOE genotype to prevalent OSAH was analyzed using generalized estimating equations to account for non-independent observations of individuals from the same sibship. Results: At least one APOE ⑀4 allele was present in 25% of subjects, with 1.3% ⑀4/⑀4 homozygotes. The prevalence of OSAH was 19%. After adjustment for age, sex, and BMI, the presence of any APOE ⑀4 allele was associated with increased odds of OSAH (OR 1.41, 95% CI 1.06 to 1.87, p ϭ 0.02). The effect was approximately twice as great in subjects Ͻ75 (OR 1.61, CI 1.02 to 2.54) as in those Ն75 years old (OR 1.32, CI 0.91 to 1.90). Exploratory analyses revealed that the strongest effect of APOE ⑀4 was in subjects age Ͻ65 (OR 3.08, CI 1.43 to 6.64), and was stronger in those with hypertension or cardiovascular disease than in those without.
Obstructive sleep apnea/hypopnea (OSAH), characterized by repetitive episodes of partial or complete upper airway closure during sleep, is a common adult disorder. OSAH associated with excessive daytime sleepiness is estimated to affect at least 2% of middle-aged women and 4% of middle-aged men in the United States, although the prevalence of OSAH independent of daytime symptoms is much higher, affecting 9 to 24% of middle-aged US adults 1 and an even higher proportion of elderly adults. 2 Obesity is an important risk factor for OSAH, although there is evidence that OSAH has a strong heritable component independent of body habitus. 3, 4 The genetic basis of this heritability remains largely unknown. In light of the known association between cardiovascular disease (CVD) and both OSAH and APOE genotype, several studies have explored the relation of APOE genotype to OSAH, with conflicting results. Among the middle-aged adult participants in the Wisconsin Sleep Cohort Study (WSCS), the presence of an APOE ⑀4 allele was associated with a twofold increased odds of OSAH, 5 although no such association was observed among the elderly participants in the Honolulu-Asia Aging Study (HAAS) 6 or in a group of Finnish OSAH patients compared with healthy controls. 7 Recently, a genome-wide linkage study in the Cleveland Family Study found suggestive evidence of linkage to AHI in a region of chromosome 19 that includes the APOE gene.
previously genotyped APOE in their participants and contributed genotype data for this analysis. Of the 700 FHS participants and 1,250 CHS participants who participated in the SHHS, APOE genotype was available for 1,778 subjects (91%). Three of these subjects were excluded due to missing data on body mass index (BMI) from the time of polysomnography. The remaining 1,775 subjects are included in this analysis. Among the FHS subjects are 123 with blood relatives included in the analysis (45 pedigrees with two siblings, 7 with three siblings, and 3 with four siblings).
Overnight polysomnography was performed in subjects' homes with the Compumedics Portable PS-2 System (Abottsville, AU) using methods previously detailed. 10, 11 Briefly, sensors were placed and equipment was calibrated during an evening visit by a certified technician. Data collection included EEG, electrooculography, submental EMG, thoracic and abdominal excursions by inductive plethysmography, nasal-oral thermistry, finger pulse oximetry, and EKG. Manual scoring of sleep and respiratory signals was performed at a central Reading Center. Sleep stages were scored according to the guidelines developed by Rechtschaffen and Kales, 12 and arousals scored according to the American Sleep Disorders Association Atlas Task Force definition. 13 Apnea was defined as a complete or almost complete cessation of airflow (Ͻ25% of baseline), as measured by the amplitude of the thermocouple signal, lasting Ͼ 10 seconds. Hypopnea was identified if the amplitude of the thermocouple or thoracic or abdominal inductance band signal decreased to Ͻ 70% of the baseline amplitude for Ͼ 10 seconds, but did not meet the criteria for apnea. Only apneas or hypopneas associated with at least a 4% oxyhemoglobin desaturation were considered in the calculation of the apnea-hypopnea index (AHI), defined as the number of apneas plus hypopneas during sleep divided by total sleep time. APOE genotype was determined in each parent cohort, under Institutional Review Board-approved informed consent specific for genetic testing, using gene amplification and restriction isotyping as previously described. 14, 15 Fasting serum total and HDL cholesterol concentration, BMI, and waist circumference were provided by the parent cohorts from the study clinic visit most nearly preceding the polysomnogram. On the evening of the polysomnogram, blood pressure and neck circumference were measured, medication use was recorded, and self-report of doctor-diagnosed angina, myocardial infarction, stroke, or congestive heart failure was obtained.
For these analyses, the presence of OSAH was defined as AHI Ն 15. The relation of APOE genotype to OSAH was examined using generalized estimating equations in order to account for non-independence of observations from siblings, using PROC GENMOD in SAS (SAS 8.0, SAS Institute, Cary, NC). Because of their known impact on AHI, all models included adjustment for sex and for age and BMI as continuous variables. Results are presented as adjusted OR with 95% CI. The primary analysis included the entire study sample, with a planned secondary analysis stratified at age 75, approximately the median age in our sample and an age between the oldest subjects in the WSCS 5 and the youngest in the HAAS 6 reports. Exploratory analyses stratified on age, using thresholds at 5-year intervals from 60 to 80, assessed the age of peak APOE effect. Analyses including an indicator variable for parent cohort (FHS vs CHS), or stratified on parent cohort, were also performed to assess heterogeneity across cohorts. Additional analyses adjusted for serum total and high density lipoprotein (HDL) cholesterol concentration, in order to assess whether the effects of APOE were mediated through effects on serum lipids, and for race and the presence of hypertension or CVD as possible confounders of the APOE-OSAH association. Exploratory analyses stratified by the presence or absence of hypertension or CVD were performed to evaluate possible effect modification by the presence of these conditions.
Results. The mean age of the 1,775 subjects was 71 years (SD 10.5, range 40 to 100) and 55% were women. Eighty-eight percent of subjects were non-Hispanic white, 12% non-Hispanic black, and less than 1% of other race/ ethnicity. The APOE ⑀4 allele frequency was 13.0% (12.0% in subjects Ͻ 75 years old, 14.0% in subjects Ն75 years old). At least one APOE ⑀4 allele was present in 25% of subjects, with only 1.3% ⑀4/⑀4 homozygotes. The distribution of APOE genotypes did not differ significantly from Hardy-Weinberg equilibrium. Due to the small number of APOE ⑀4 homozygotes, the primary analyses compared subjects with any APOE ⑀4 allele to those without. As expected, the presence of the APOE ⑀4 allele was associated with a significantly higher total cholesterol and lower HDL cholesterol, despite slightly less adiposity (table 1) . APOE ⑀4-positive subjects did not differ significantly from ⑀4-negative subjects in smoking history or mean FEV 1 . APOE ⑀4 positivity was associated with a somewhat higher prevalence of coronary heart disease, stroke, and hypertension, although these differences were not significant. The median AHI across all study subjects was 4.8 (range 0 to 149, interquartile range 1.6 to 11.9); 19.0% had OSAH, defined as an AHI Ն 15, including 241 (18.0%) of 1,336 subjects without and 97 (22.1%) of 439 with an APOE ⑀4 allele. After adjustment for age, sex, and BMI, the presence of any APOE ⑀4 allele was associated with a 41% increased odds of OSAH (adjusted OR 1.41, CI 1.06 to 1.87; table 2). Adjustment for race had no impact on the estimated effect of APOE ⑀4 on OSAH, but there were too few non-white subjects to make meaningful comparisons across races. Neither total nor HDL cholesterol was significantly associated with the presence of OSAH, and adjustment for these variables did not appreciably alter the association of APOE ⑀4 with OSAH (age-, sex-, and BMIadjusted OR 1.45 with total cholesterol in model, 1.47 with HDL cholesterol in model). The association of APOE ⑀4 with OSAH was similar in men and women, with an ageand BMI-adjusted OR of 1.46 in men and 1.42 in women. The association of APOE ⑀4 with OSAH was also similar in non-obese (BMI Ͻ 30, n ϭ 1,289) and obese (BMI Ն 30, n ϭ 486) subjects, with age-and sex-adjusted OR of 1.34 in non-obese and 1.47 in obese subjects. The 24 subjects homozygous for APOE ⑀4 did not have increased odds of OSAH compared to subjects with no ⑀4 allele (age, sex, and BMI-adjusted OR 0.86, CI 0.26 to 2.89), although the small number of subjects makes the effect estimate unreliable.
At least one APOE ⑀2 allele was present in 15.6% of subjects. Inclusion in the models of a variable reflecting the presence or absence of an APOE ⑀2 allele had no meaningful impact on the association of APOE ⑀4 with OSAH (age-, sex-, BMI-, and ⑀2-adjusted OR 1.38, CI 1.04 to 1.83).
The presence of an APOE ⑀2 allele was in the direction of reduced risk for OSAH but was not significant (age-, sex-, BMI-, and ⑀4-adjusted OR 0.80, CI 0.55 to 1.15). The association of the APOE ⑀4 allele with OSAH was approximately twice as great in subjects Ͻ75 than in those Ն75 years old (see table 2). Although age 75 was chosen a priori for age stratified analyses, exploratory analysis of age thresholds at 5-year intervals was undertaken to further explore age dependency of the association of APOE to OSAH. The age of peak effect was approximately 65 years. Among subjects age Ͻ65, the age, sex, and BMI-adjusted OR was 3.08 (CI 1.43 to 6.64), vs an adjusted OR of 1.25 in subjects age Ն65 (CI 0.93 to 1.69). Despite these differences in estimated effect, formal tests of interaction of age group by APOE genotype were not significant for either age 75 (p ϭ 0.56) or age 65 (p ϭ 0.10). The age of subjects enrolled in the SHHS from the CHS cohort are considerably older (mean [SD] age 77.6 [4.8] years) than those enrolled from the FHS cohort (59.8 [8.9] years), and all subjects age Ͻ65 years are from the FHS cohort. We therefore evaluated whether cohort effects other than age might account for the apparent age-dependency of the APOE-OSAH association. Inclusion of an indicator variable for parent cohort (FHS vs CHS) had no impact on the magnitude of the APOE-OSAH association. When the analysis was stratified by parent cohort, the age, sex, and BMIadjusted OR in the FHS sample (2. Using a threshold of AHI Ն 30 to define OSAH, the * Adjusted in total sample and within each stratum for age, sex, and body mass index. Generalized estimating equations used to account for non-independent observations of individuals from the same sibship. † Hypertension defined as systolic blood pressure Ͼ140 mm Hg, diastolic blood pressure Ͼ90 mm Hg, or taking antihypertensive medication. ‡ Cardiovascular disease (CVD) is defined as the self-report of doctor diagnosed angina, myocardial infarction, stroke, or congestive heart failure.
prevalence of OSAH in the study sample was 6.4%. The association of APOE ⑀4 allele with OSAH defined in this way was similar to the association observed when OSAH was defined as AHI Ն 15, and the apparent agedependency of the association was even more striking. For the entire sample, the age-, sex-, and BMI-adjusted OR was 1.46 (CI 0.95 to 2.23). In subjects age Ͻ75 the adjusted OR was 2.49 (CI 1.24 to 5.02), while in those age Ն75 the adjusted OR was 1.04 (CI 0.59 to 1.83). Stratification of the sample by the presence or absence of hypertension, defined as systolic blood pressure Ͼ 140, diastolic blood pressure Ͼ 90, or taking antihypertensive medication, revealed that the age-, sex-, and BMI-adjusted association of APOE ⑀4 with OSAH was seen primarily in hypertensive subjects (see table 2 ). When this analysis was further stratified by age above or below 75, the association of APOE ⑀4 with OSAH was stronger in the hypertensive subjects age Ͻ75. The magnitude of the association of APOE ⑀4 with OSAH was also greater in subjects reporting prevalent CVD than in those free of CVD (see table 2), and this effect was also stronger in younger subjects. Inclusion of prevalent hypertension and CVD as covariates in the main analysis did not, however, diminish the strength of the association of APOE ⑀4 with OSAH.
Periodic breathing, defined as cyclic waxing and waning of thermocouple or inductance band signals lasting for at least 10 minutes, was present in 5% of subjects. The APOE ⑀4 allele was not associated with periodic breathing, with an age-, sex-, and BMI-adjusted OR of 0.94 (CI 0.57 to 1.55). In order to assess whether sleep state instability might mediate the APOE-OSAH association, we analyzed the relation of APOE genotype to arousal index. Overall, 24% of subjects had an arousal index Ն 25. Despite a moderate correlation between AHI and arousal index (r ϭ 0.49), there was no significant association between the presence of the APOE ⑀4 allele and elevated arousal index in either unadjusted or age-, sex-, and BMI-adjusted models, with the direction of effect toward a lower arousal index in those with the APOE ⑀4 allele.
Discussion. These findings support the previously reported association between the APOE ⑀4 allele and OSAH observed in the WSCS. 5 The magnitude of the APOE ⑀4-OSAH association was similar in men and women, and in obese and non-obese subjects, but declined with advancing age. The strongest APOE ⑀4-OSAH association was seen in individuals under age 65; however, there were too few subjects under age 60 to determine the pattern of age dependency at younger ages. A similar age dependency has been reported for the association of APOE ⑀4 with coronary atherosclerosis 16 and Alzheimer disease (AD).
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The FHS cohort is considerably younger than the CHS cohort, suggesting the possibility that cohort effects other than age might lead to an apparent age-dependency of the APOE-OSAH effect; however, magnitude of the APOE-OSAH association is considerably greater in FHS subjects Ͻ65 years old than in those Ն65. This suggests that the age effect observed for the entire study sample is not likely to reflect confounding by cohort differences other than age.
Given the substantially higher mean AHI in older subjects, it is likely that this age dependency reflects competing risk factors for OSAH in the elderly. As the APOE ⑀4 allele frequency was somewhat higher in older than in younger subjects (14.0% vs 12.0%), it is unlikely that age-dependency of the APOE-OSAH association is due to excess death or other loss to follow-up among APOE ⑀4-positive subjects with OSAH. In either case, the disagreement between prior epidemiologic studies of the APOE-OSAH association 5, 6 may be explained by age-dependency of the association.
Our sample had insufficient minority representation to explore effect modification by race, and included few subjects of Asian ancestry. The prevalence of APOE ⑀4 positivity in our sample (25%) was similar to that in the WSCS (28%), but somewhat higher than that in the HAAS (18%). The lower prevalence in that cohort may reflect the known lower prevalence of the APOE ⑀4 allele in Japanese. 17 In the study of Finnish OSAH patients and controls, the prevalence of APOE ⑀4 positivity was 34%. 7 While a similar association of APOE ⑀4 to OSAH would be expected across races if the APOE ⑀4 allele were a functional polymorphism causing OSAH, heterogeneity of the effect of APOE genotype across different genetic backgrounds (predominantly northern European in WSCS vs Japanese in HAAS) cannot be excluded. As is the case for AD, the APOE ⑀2 allele was associated with reduced odds of OSAH, although this effect was not significant.
In exploratory analyses, the present study finds evidence of a possible interaction of APOE ⑀4 and hypertension in causing OSAH. This is consistent with evidence that hypertension may act synergistically with APOE ⑀4 to increase risk of cognitive impairment 18 and that treatment of hypertension may decrease the risk of AD. 19 The greater risk of OSAH in APOE ⑀4-positive subjects with prevalent CVD might also reflect an interaction of APOE ⑀4 with other cardiovascular risk factors in mediating the pathophysiologic processes resulting in OSAH, but raises the intriguing possibility that APOE genotype may modify the cardiovascular risk of OSAH. While these findings suggest effect modification by hypertension or CVD, there is no evidence from this study for confounding of the APOE-OSAH association by these factors.
The mechanism of the effect of APOE genotype on OSAH is unknown, although the potential importance of a causal association would be substantial. As at least one APOE ⑀4 allele is present in approximately 25% of the population, the observed OR and their 95% CI suggest that 9% (CI 1.5 to 18%) of all OSAH cases in the adult population and 34% (CI 10 to 58%) of OSAH cases in adults under age 65 may be attributable to the APOE ⑀4 genotype. OSAH is most often the result of an anatomically small or collapsible pharyngeal airway, often due to obesity, in combination with a sleep-induced fall in pharyngeal dilator muscle activity. 20 It does not appear that APOE ⑀4 genotype has an adverse impact on adipos-ity, as APOE ⑀4-positive subjects were less obese whether assessed by BMI, waist girth, or neck circumference. Unless APOE has an obesityindependent effect on upper airway anatomy, it is likely that its effect is mediated through alterations in ventilatory control mechanisms. The lack of association between APOE genotype and elevated arousal index suggests that sleep state instability probably does not mediate such an effect. Although pure central sleep apnea is uncommon in younger subjects, and we did not observe an association of APOE ⑀4 with classic periodic breathing, cyclic decreases in output from respiratory motoneurons innervating upper airway dilator muscles has been demonstrated in obstructive as well as central sleep apnea. 21, 22 Thus, central mechanisms may result in obstructive apnea or hypopnea in anatomically susceptible individuals.
As expected, the APOE ⑀4 allele was associated with significantly higher total cholesterol and lower HDL cholesterol. Higher cholesterol level has been shown to predict development of OSAH, 23 and in the SHHS cohort AHI has a significant positive correlation with total cholesterol in men, and a significant negative correlation with HDL cholesterol in women. 24 While it would be attractive to attribute the APOE-OSAH association to cholesterol-related mechanisms, the magnitude of the association is not diminished by inclusion of total or HDL cholesterol in the regression models. Therefore, by the standard assumptions of mediation analysis, 25 the effect of APOE on OSAH is not likely to be mediated through the wellknown effects of APOE on serum cholesterol concentration. It is possible that APOE ⑀4 exerts its effect as part of the neuropathologic processes that are implicated in the development of APOE ⑀4-related AD. Despite the earlier age at onset of OSAH, some pathologic changes associated with AD can be observed even in asymptomatic carriers of the APOE ⑀4 allele. 26 While the pathogenesis of APOE ⑀4-related AD is complex, and its relevance to OSAH remains speculative, degeneration of brainstem respiratory centers with consequent decreased activity of respiratory motoneurons innervating the pharyngeal dilator muscles is a plausible mechanism underlying the APOE-OSAH association. An analogous process in patients with multiple system atrophy has been suggested by the finding that the severity of OSAH in these patients is highly correlated with loss of cholinergic projections from the pedunculopontine tegmental and laterodorsal tegmental nuclei. 27 Alternatively, given its role in lipid metabolism, APOE might influence ventilatory drive through effects on leptin or other adipokines, although such effects remain to be demonstrated.
